Dr. Eckburg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Education & Training
- Stanford Health Care2004
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Infectious Disease, 2000 - 2002
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1996 - 1999
- Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1996 - 1997
- Rush Medical College of Rush University Medical CenterClass of 1996
Certifications & Licensure
- CA State Medical License 1997 - 2025
- HI State Medical License 1999 - 1999
Clinical Trials
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections Start of enrollment: 2007 Mar 01
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections Start of enrollment: 2007 Feb 01
- Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia Start of enrollment: 2007 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 5211 citationsDiversity of the human intestinal microbial flora.Paul B. Eckburg, Elisabeth M. Bik, Charles N. Bernstein, Elizabeth Purdom, Les Dethlefsen
Science. 2005-06-10 - 118 citationsArchaea and Their Potential Role in Human DiseasePaul B. Eckburg, Paul W. Lepp, David A. Relman
Infection and Immunity. 2003-02-01 - 2965 citationsMetagenomic Analysis of the Human Distal Gut MicrobiomeSteven R. Gill, Mihai Pop, Robert T. DeBoy, Paul B. Eckburg, Peter J. Turnbaugh
Science. 2006-06-02
Press Mentions
- Recida Therapeutics Raises $8.5M in Series AFebruary 9th, 2019
- Frazier Healthcare Partners Launches Recida Therapeutics to Develop Novel Therapeutics for Serious Antibiotic-Resistant InfectionsFebruary 6th, 2019
- UTILITY Receives Qualified Infectious Disease Product Designation from the U.S. FDAMay 21st, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: